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Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear receptors controlling many important physio-
logical processes, including lipid and glucose metabolism, energy homeostasis, inﬂammation, as well as cell proliferation and
diﬀerentiation. In the past decade, intensive study of PPARs has shed novel insight into prevention and treatment of dyslipidemia,
insulin resistance, and type 2 diabetes. Recently, a large body of research revealed that PPARs are also functionally expressed in
reproductive organs and various parts of placenta during pregnancy, which strongly suggests that PPARs might play a critical role
in reproduction and development, in addition to their central actions in energy homeostasis. In this review, we summarize recent
ﬁndings elucidating the role of PPARs in female reproduction, with particular focus on evidence from gene knockout and trans-
genic animal model study.
Copyright © 2008 Jichun Yang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are
members of the ligand-activated nuclear hormone receptor
superfamily of 49 members that participate in many phys-
iological functions [1]. To date, three isotypes, designated
as PPARα,P P A R β/δ,a n dP P A R γ, have been identiﬁed in
many species, including frogs, rodents, and humans [2, 3].
PPARα is highly expressed in liver, kidney, heart, skeletal
muscle, and other tissues involving fatty acid oxidation and
it had been demonstrated to be the central regulator of fatty
acid β-oxidation, fatty acid (FA) transport, and lipoprotein
synthesis in these tissues. Activation of PPARα by its natu-
ral or synthetic ligands enhances FA uptake and oxidation
in liver, which is beneﬁcial for ameliorating dyslipidemia
[4, 5]. PPARγ is predominantly expressed in adipose tis-
sue and is a key regulator of adipocyte diﬀerentiation and
triglyceride storage, whereas PPARβ/δ is ubiquitously ex-
pressed in almost all tissues and believed to be involved in
lipid metabolism [4, 6]. In contrast to intensive research into
PPARγ and PPARα, little exists for PPARβ/δ. After bind-
ing by their endogenous ligands, such as 15-deoxy-Δ12,14-
prostaglandin J2 (15dPGJ2) and long-chain FAs, or exoge-
nous synthetic agonists, such as thiazolidinediones (TZDs)
and ﬁbrates, PPARs will heterodimerize with another nu-
clear receptor called retinoid X receptor alpha (RXRα). The
PPARs/RXRα heterodimer binds to a speciﬁc DNA sequence
called PPAR-responsive element (PPRE) located in promoter
regions of the target genes to initiate or silence gene tran-
scription. A typical PPRE consists of a repeat AGGTCA sepa-
rated by one nucleotide. However, activation of PPARs is far
more complex than this, with complicated cross-talk among
PPARs, RXRs, ligands, corepressors, coactivators, and many
other factors [7, 8].
Because PPARs play key roles in regulating energy
homeostasis, particularly FA oxidation and carbohydrate
metabolism, numerous studies have been conducted in the
pastdecadetodevelopsyntheticPPARagonistsfortherapeu-
tic treatment of metabolic diseases, including dyslipidemia,
insulin resistance, and type 2 diabetes. Long before being
identiﬁed as PPARα agonists, ﬁbrates were clinically pre-
scribed for treatment of dyslipidemia. Subsequently, TZDs,
structural analogues of ﬁbrates, were shown to selectively ac-
tivate PPARγ [7, 9–11]. To date, several TZDs, including pi-
oglitazoneandrosiglitazone,improveglycemiccontrolinpa-
tients with type 2 diabetes or glucose intolerance via their
insulin-sensitizing activity, mainly achieved by preventing
FA uptake and adipose deposition in insulin-sensitive tissues2 PPAR Research
suchasliver,muscle,andpancreas[7,9–11].Inaddition,po-
tent agonists for activation of multiple PPAR isotypes now in
development, such as dual PPARα/γ agonists, have consider-
able promise for improving glycemic control with fewer side
eﬀects. As well, PPARβ/δ agonists are currently under devel-
opment.
The nutrients glucose and FA and fuel sensors insulin
and leptin have long been known to be critical in regulating
female reproduction [12–14]. During the onset of puberty,
molecules such as leptin and neuropeptide Y might function
as energy sensors and initiate reproduction processes un-
der conditions of suﬃcient body energy storage [13, 15, 16].
Given the well-documented central roles of PPARs in en-
ergy homeostasis and because energy status is directly linked
to reproduction [13, 14], it is reasonable to speculate that
PPARs may play important roles in female reproduction.
In fact, many recent studies have examined the potential
role of PPARs in reproduction. In rodents, PPAR knock-
out mouse models have provided direct evidence of a criti-
cal role of PPARs in reproduction and placenta development
(Table 1). PPARγ-null mouse fetuses were shown to die by
embryonic day 10 because of failed formation of the vascu-
lar labyrinth [17, 18], and PPARβ/δ-null mice also exhibited
abnormal placenta during development [19]. In contrast to
PPARγ-a n dP P A Rβ/δ-null mice, PPARα-null mice displayed
no placental abnormality but, rather, increased risk of ma-
ternal abortion and oﬀspring neonatal mortality [20]. Sub-
sequent studies involving RT-PCR, in situ hybridization, im-
munohistochemistry, and Northern and Western blot analy-
sis further revealed all three PPAR isotypes are expressed in
reproductive tissues such as testis (sperm), ovary (oocyte),
as well as various parts of the placenta of rat, mouse, and
human [12, 21, 22]. Importantly, pregnant rats given oral
troglitazone showed signiﬁcantly increased placental PPARγ
expression as well as reduced mortality of fetuses by about
50% [23]. Loss-of-function mutations of PPARs have pro-
vided excellent models for studying the roles of PPARs in hu-
man reproduction and placenta development. To date, three
groups of loss-of-function mutations of PPARγ have been
described [6, 24–26]. In one study, about 40% of female sub-
jects with loss-of-function mutations of PPARγ had polycys-
tic ovary syndrome (PCOS) [6], which has been believed to
beassociatedwithinfertilityinwomen.Consistentwiththese
observations, administration ofinsulin-sensitizers TZDsand
metformin improved ovulation function and fertility and
enhanced growth hormone (GH) secretion in women with
PCOS [27, 28]. Collectively, these ﬁndings imply an impor-
tant role for PPARs in mammalian reproduction.
In this review, we discuss PPARs expression in female
reproductive tissues and their roles in female reproduction,
with a focus on genetically manipulated mice.
2. PPARs: TISSUE DISTRIBUTION IN FEMALE
REPRODUCTIVE SYSTEM
2.1. Hypothalamic-pituitaryaxis
All three PPAR isotypes have been detected in the mouse
pituitary gland [29]. PPARγ is highly expressed in normal
human pituitary gland and in all normal pituitary secreting
cell lines [30]. Because of its antiproliferative eﬀects in pi-
tuitary cells, activation of PPARγ by TZDs inhibited the de-
velopment of pituitary adenomas in mice and humans [31].
Despite its presence in the hypothalamic-pituitary axis, the
precise roles of PPARγ in reproductive cells remain poorly
understood. Although PPARγ expression is evident in pitu-
itary tissue, TZD treatment failed to aﬀect the in vitro secre-
tion of ovine pituitary hormones, including prolactin (PRL),
growth hormone (GH), follicle-stimulating hormone (FSH),
and luteinizing hormone (LH), and also no alteration of the
LH secretion was observed in LbetaT2 cells, a murine go-
nadotropic pituitary tumor cell line [12].
2.2. Ovary
All three isotypes of PPAR are expressed in ovarian tissue.
PPARα and PPARβ/δ are expressed primarily in the theca
and stroma tissues [32], whereas PPARγ,m o r ee x t e n s i v e l y
studied, was detected in ovaries of mouse, rat, pig, sheep,
cow, and human. In the ovaries of rodents and ruminants,
PPARγ is highly expressed in granulosa cells, with lower ex-
pression in theca cells and the corpus luteum [12]. In hu-
mans, PPARγ was present in granulosa cells collected dur-
ing oocyte aspiration from women undergoing treatment
for in vitro fertilization [33]. Unlike the constant expression
of PPARα and PPARβ/δ throughout follicular development
and the ovarian cycle, the expression of PPARγ is downregu-
lated in response to LH surge. PPARγ expression seems to be
tightly regulated in the ovary, and its regulatory expression is
the primary mechanism by which LH inﬂuences the activity
of PPARγ [34].
2.3. Uterusandplacenta
Although all three PPAR isotypes are functionally expressed
in uterus, they display diﬀerent expression proﬁles with the
development of placenta in pregnancy [35–37]. In endome-
triaofewe,PPARαexpressiondeclinesbetweenday7andday
17 of pregnancy, whereas PPARβ/δ is constantly expressed
at all developmental stages and PPARγ expression is errati-
cally regulated. In addition, RXRs diﬀer from that of PPARs,
which suggests that diﬀerent PPAR/RXR heterodimers might
form and function distinctly as development proceeds [35].
All three PPAR isotypes have been reported in placenta in
rodents and humans. PPARγ was the ﬁrst to be detected in
a human choriocarcinoma-derived JEG cell line by North-
ern blot analysis [34]. In human placenta, PPARγ is ex-
pressed in early and term villous trophoblasts and in extrav-
illous trophoblasts in ﬁrst-trimester placentas [21]. PPARγ
was also detected in mouse placenta as early as embryonic
day 8.5 [38] and in rat placenta by day 11 [23]. In mice,
PPARγ is expressed in spongiotrophoblasts and in the vascu-
lar labyrinth that forms the interface between maternal and
fetal circulation to control nutrient exchange [23]. In rodent
placenta, PPARα and PPARβ/δ are present in the junctional
zone, which has invasive and endocrine functions, and in the
labyrinth,whereasinhumanplacenta,theyareinvilloustro-
phoblasts, particularly syncytiotrophoblasts [39]. However,Jichun Yang et al. 3
in cultured villous trophoblasts of human term placenta,
PPARαandPPARβ/δ transcriptlevelswerehigherincytotro-
phoblasts than in syncytiotrophoblasts [40].
2.4. Mammarygland
All three isotypes of PPAR are detected in rodent mammary
glandandhumanbreastcelllines[41–44].Duringpregnancy
and lactation, the PPARα and γ mRNAs decreased while the
PPARβ/δ mRNA remained relatively unchanged in mouse
mammary gland [41].
3. PPARα AND FEMALE REPRODUCTION
During pregnancy, placental transfer of FA and other nutri-
ents from the mother to the fetus is crucial for adequate fetal
growth and development, and PPARα might play a crucial
role in this process because of its central role in FA trans-
port and oxidation [4, 10, 39]. Recently, gemﬁbrozil and
cloﬁbrate, two PPARα agonists, were shown to downregu-
latehumanchorionicgonadotrophinandupregulateproges-
terone secretion in human trophoblasts, which suggests that
activation of PPARα might be beneﬁcial for the secretion of
thesehormones,soessentialformaintainingpregnancy[45].
More recently, evidence for a key role of PPARα in placenta
development was demonstrated by increased abortion rate
(by 20%) in PPARα-null mice without diabetes [4, 20]. In
PPARα-null mice with diabetes, the mean abortion rate was
approximately 50%, as compared with 8.3% for wild-type
mice. Moreover, PPARα-null mice showed higher neonatal
mortalitythanwild-typemice:formicewithoutdiabetes,the
rate was 13.3% versus 5.1%, respectively, and for mice with
diabetes, 78.9% versus 27.7% [20]. Thus, PPARα might have
an important role in maternal-fetal nutrient exchange, and
its deﬁciency could be deleterious to fetal development. This
study further supported that tight control of blood glucose is
beneﬁcial for improving the fertility of diabetic women and,
as clearly indicated in this study, abortion rate and neonatal
mortality were increased in both wild-type and PPARα-null
mice with diabetes.
Controversially,some otherreports indicated thatactiva-
tionofPPARαmightbedeleterioustodevelopmentoffemale
reproductive cells. PPARα can bind to estrogen response el-
ements and act as a competitive inhibitor of estrogen recep-
tor [46, 47]. Activation of PPARα decreased the expression
and activity of aromatase in granulosa cells [48], thus re-
sulting in decreased estradio synthesis. More recently, treat-
ment with the PPARα agonist fenoﬁbrate decreased the level
of aromatase in wild-type mice but enhanced it in PPARα-
null mice [49]. A critical role for PPARα in mammary gland
function was supported by a recent study in which trans-
genic mice expressing a constitutively activated PPARα form
(VP16PPARα) in the stratiﬁed epithelia had a severe defect
in mammary gland development and lactation during preg-
nancy, resulting in 100% neonate mortality [50]. Taken to-
gether, these observations reveal that PPARα plays an impor-
tant role in mammalian female reproduction, but further re-
search work is required to clarify its deﬁnite role and under-
lying molecular mechanism(s).
4. PPARβ/δ AND FEMALE REPRODUCTION
PPARβ/δ is ubiquitously expressed in the ovary at a con-
stant level during the estrous cycle and pseudopregnancy
[51], which suggests that PPARβ/δ may be involved in nor-
mal ovarian function in theca, stroma, and luteal cells. One
study showed that PPARβ/δ mRNA was almost absent on
mouse embryo days 1–4 but was signiﬁcantly expressed in
the subluminal stroma surrounding blastocysts on day 5, just
after embryo implantation. Subsequently, PPARβ/δ expres-
sion was increased in the decidua on days 6–8 [36, 52]. A
similar process was observed in rat as well, intense PPARβ/δ
immunostaining was observed in rat decidua under artiﬁ-
cial decidualization but not in uninjected control horns [53].
These data suggest that PPARβ/δ expression at implantation
sites requires an active blastocyst or analog and may play an
essential role in blastocyst implantation.
A large body of research has indicated that PPARβ/δ me-
diates the important role of COX-2-derived prostaglandin I2
(prostacyclin, PGI2) in pregnancy. COX-2 knockout female
mice displayed decreased fertility, in part due to deﬁciency of
blastocyte implantation and decidualization [52, 54]. Treat-
ment of these mice with a PGI2 analogue, carboprostacy-
clin, or the PPARβ/δ-selective agonist L-165041 restored im-
plantation [52]. PGI2 is the most abundant prostaglandin at
implantation sites where PPARβ/δ and COX-2 were colocal-
ized and strongly upregulated during pregnancy in a similar
manner [52]. As a potent endogenous PPARβ/δ ligand, PGI2
can act as a vasoactive agent to increase vascular permeabil-
ity [55, 56] and blastocyst hatching [57], so the high expres-
sion of PPARβ/δ in the subluminal stroma at implantation
sites might mediate this process, facilitating the implantation
of the embryo [58]. This suggestion was further conﬁrmed
by placentas of PPARβ/δ-null mice displaying abnormal vas-
cular development [19] and that giant-cell diﬀerentiation
of placentas requires an intact PPARβ/δ signaling pathway
[57].
In addition tothe important roles of PPARβ/δ atimplan-
tation sites of the maternal body, the expression and func-
tion of PPARβ/δ in the embryo are of interest. Compared to
the development of in vivo embryos, cultured embryos, such
as in vitro fertilization (IVF) embryos, are retarded because
they lack the protective environment of the maternal body
[59]. Supplementing culture media with milepost, a stable
analog of PGI2, enhanced mouse blastocyst hatching [60].
Recent work showed that preimplantation embryos express
PPARβ/δ, which is essential for the enhancing eﬀect of PGI2
and the spontaneous progression of the embryos. PGI2 pro-
moted the development of wild-type embryos in vitro and
enhanced their implantation potential but had no eﬀect on
PPARβ/δ-null embryos [61].
PPARβ/δ is expressed ubiquitously at higher levels dur-
ing embryogenesis than in adulthood [62, 63]. In addition,
homozygous loss of PPARβ/δ caused frequent embryonic
lethality, but surviving PPARβ/δ-deﬁcient oﬀspring did not
die postnatally, which suggests that the essential function of
the receptor is restricted to the gestational period [19].
Given the roles of PPARβ/δ in embryo development
and implantation, the activity of PPARβ/δ agonists under4 PPAR Research
Table 1: Studies of reproductive phenotypes of female PPARα,P P A R β/δ,a n dP P A R γ-null or transgenic mice.
PPAR isotype Reproductive phenotypes References
PPARα KO Maternal abortion and neonatal death; altered
ovarian estradiol production
Yessoufou et al. [20], Lefebvre et al.
[4]
TG Defect in mammary gland development; defect in
lactation during pregnancy Yang et al. [50]
PPARβ/δ KO Placental defects; frequent (>90%) midgestation
lethality; placenta lipid accumulation defects Barak et al. [19], Nadra et al. [57]
PPARγ KO
Embryonic death at embryo day 10; embry-
onic lipid droplets lacking; placental malformed
labyrinth zone; toxic milk
Barak et al. [17], Kubota et al. [18],
Wan et al. [71]
TG Exacerbates mammary gland tumor development Saez et al. [73]
KO: global or tissue-speciﬁc knockout; TG: tissue-speciﬁc transgenic.
development should be carefully evaluated to avoid possible
complications in pregnancy with their use.
5. PPARγ AND FEMALE REPRODUCTION
After ovulation, the expression of PPARγ in the corpus lu-
teum increases, otherwise the corpus luteum regresses and
PPARγ expression decreases if no fertilization or embryo im-
plantation occurs [64, 65]. Thus, PPARγ might play a role in
fertilitycontrol.Indeed,micewithspeciﬁcdeletionofPPARγ
in granulosa cells exhibited reduced fertility [66]. Luteal ex-
pression of PPARγ might be important for the pregnancy,
possibly via maintaining production of progesterone to sup-
port implantation and gestation [67].
PPARγ-null embryos were shown to die by embryonic
day 10 [17], as a result of placenta alteration and mal-
formed vascular labyrinth due to PPARγ deﬁciency, which
disrupts the interface between trophoblasts and the fetal en-
dothelium and leads to embryonic myocardial thinning. A
tetraploid-rescued mutant overcame the placenta defect for
survival to term. Consistent with this observation, an RXRα-
(PPARγ hetero-partner) or RXRα/RXRβ-null mutant exhib-
ited a similar phenotype to that of PPARγ-null mice [17, 68].
The expression of Mucin 1 (MUC1), a PPARγ target gene,
is lost in PPARγ-null mice, whereas its expression in wild-
type mice can be upregulated by PPARγ agonist treatment.
MUC1 expressed in the apical surface of the labyrinth helps
in diﬀerentiation of trophoblast stem cells and invokes de-
velopmental and functional analogies between the placental
blood sinuses and luminal epithelia [69].
During early term pregnancy, placental trophoblasts in-
vade the uterine wall and establish the maternal-fetal ex-
change. PPARγ plays a dominant role in this process. The
diﬀerentiation of the placenta is characterized by fusion of
cytotrophoblasts into syncytiotrophoblasts, which are more
resistant than cytotrophoblasts to hypoxic injury. Activation
of PPARγ stimulates this diﬀerentiation process [21]. PPARγ
agonists increase FA uptake and adipose accumulation in
trophoblasts [70], and PPARγ-null or RXRα-null murine
embryos show fewer lipid droplets than wild-type embryos
[17, 68], which suggests an important role of PPARγ in pro-
viding suﬃcient nutrients for embryo development. More-
over, it is indicated in one latest study that PPARγ deletion in
mammary gland resulted in the production of “toxic milk”
containing elevated levels of inﬂammatory lipids, which re-
sults in inﬂammation, alopecia, and growth retardation in
the nursing neonates [71]. Peroxisome proliferator-activated
receptor-binding protein (PBP) serves as an anchor for re-
cruiting PPAR mediator complexes, and is necessary for
activation of PPARs. Moreover, speciﬁc knockout of PBP
in mouse mammary gland resulted in a severe defect in
mammary gland development, indeed the PBP-null mam-
mary gland failed to produce milk for nursing neonates
during lactation [72]. These studies clearly indicated that
PPARγ/PPAR-binding protein expression are also vital for
providing high-quality milk for nursing the neonates and
protecting them from inﬂammatory lipids [71]. Interestingly
and unexpectedly, constitutive expression of an active form
of PPARγ (Vp16PPARγ) in mammary gland exacerbated
mammary gland tumor development via enhanced Wnt sig-
naling [73].
Proinﬂammatory proteins and cytokines are associated
with term and preterm labor and stimulate uterine contrac-
tion [74]; PPARγ might be implicated in this process because
of its ability to suppress inﬂammatory cytokine secretion
[75]. The natural ligands of placental PPARγ may be present
in maternal circulation, which could be naturally occurring
prostanoids or FAs and some reproductive hormones. This
hypothesis is supported by the observation that serum from
pregnant women activated PPARγ expression in JEG-3 cells,
whileserumfromnonpregnantwomenhavingnosucheﬀect
[76].
In addition, as a target gene of PPARγ, another nuclear
receptor, liver X receptor (LXR), participates in regulation of
female reproduction. The two isforms, α and β,b o t ha c ta s
transcription factors activated by binding of speciﬁc choles-
terol metabolites [77]. LXRs play important roles in many
metabolic pathways, such as cholesterol, lipid, and carbohy-
drate metabolism. In addition to these regulatory actions,
LXRs aﬀect reproductive function. Mice deﬁcient in LXRα,
LXRβ, or both showed decreased ability to conceive and
fewer pups per litter as compared with wild-type mice [78].
Aswell,bothLXRαandβareexpressedinmouseoocytesand
seemtoaﬀectovarianfunction[78].Lipiddistributioninthe
uterus plays a critical role for its function. LXR prevents ac-
cumulation of cholesteryl esters in the mouse myometriumJichun Yang et al. 5
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Figure 1: Schematic presentation of regulatory roles of PPARs in reproduction and development.
by controlling the expression of genes (ABCA1 and ABCG1)
involved in cholesterol eﬄux and storage. As well, mice lack-
ing LXRβ showed a contractile activity defect induced by
oxytocin or PGF2α [79]. Taken together, gene knockout re-
sults suggest that PPARγ/LXR might participate in embry-
onic development by sensing changes in levels of nutrients,
hormones, and/or other signals.
6. CONCLUSION
A large body of research has revealed that in addition to their
central roles in regulating FA oxidation and glucose home-
ostasis, PPARs are highly expressed in reproductive tissues
and placenta, so PPARs might also be key regulators of re-
production and development (Table 1). At the early stage of
sexual maturation, PPARs might be activated in response
to energy status and/or circulating hormones for involve-
ment in maturation of reproductive cells. During gestation,
PPARs are highly expressed in trophoblasts and directly in-
volved in cytotrophoblast diﬀerentiation and function, pos-
sibly functioning as energy-signal sensors and transporters
for nutrients and gases between maternal and fetus circula-
tiontoprovidesuﬃcientnutrientsfordevelopmentofthefe-
tus(seeFigure 1).Moreover,PPARsalsoplayimportantroles
in mammary gland development and maternal PPARs are
vital for producing high-quality milk for nursing neonates.
However, further research is required to address the follow-
ing questions. (1) What are the natural ligands for activa-
tion of PPARs in reproduction and development, nutrients,
sexual hormones, or other factors? (2) What are the under-
lying molecular mechanisms of PPAR activation in response
to their natural ligands? Given the critical roles of all three
PPAR isotypes in female reproduction, caution should be
taken in the clinical use of PPARα and PPARγ agonists in
young women.
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